Achilles Historical Income Statement

ACHL Stock  USD 1.12  0.01  0.88%   
Historical analysis of Achilles Therapeutics income statement accounts such as Tax Provision of 39.2 K, Depreciation And Amortization of 2.8 M or Selling General Administrative of 16.7 M can show how well Achilles Therapeutics PLC performed in making a profits. Evaluating Achilles Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Achilles Therapeutics's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Achilles Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Achilles Therapeutics PLC is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

About Achilles Income Statement Analysis

Achilles Therapeutics PLC Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Achilles Therapeutics shareholders. The income statement also shows Achilles investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Achilles Therapeutics Income Statement Chart

At this time, Achilles Therapeutics' Interest Expense is quite stable compared to the past year. Tax Provision is expected to rise to about 39.2 K this year, although the value of Net Loss is projected to rise to (60.9 M).

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.
Most accounts from Achilles Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Achilles Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
At this time, Achilles Therapeutics' Interest Expense is quite stable compared to the past year. Tax Provision is expected to rise to about 39.2 K this year, although the value of Net Loss is projected to rise to (60.9 M).
 2022 2023 2024 2025 (projected)
Total Operating Expenses78.4M75.3M86.5M58.4M
Cost Of Revenue3.7M4.7M5.4M2.8M

Achilles Therapeutics income statement Correlations

-0.93-0.970.97-0.981.00.99-0.941.0-0.93-0.98-0.941.0-0.951.0-0.39-0.49
-0.930.92-0.970.98-0.94-0.950.99-0.941.00.981.0-0.940.97-0.940.520.61
-0.970.92-0.940.97-0.97-0.960.92-0.970.920.970.94-0.980.91-0.970.260.47
0.97-0.97-0.94-0.970.980.99-0.970.97-0.97-0.97-0.970.98-0.950.98-0.55-0.57
-0.980.980.97-0.97-0.98-0.980.99-0.980.981.00.99-0.980.98-0.980.420.57
1.0-0.94-0.970.98-0.981.0-0.951.0-0.94-0.98-0.951.0-0.951.0-0.41-0.49
0.99-0.95-0.960.99-0.981.0-0.950.99-0.95-0.98-0.961.0-0.951.0-0.45-0.52
-0.940.990.92-0.970.99-0.95-0.95-0.940.990.990.99-0.940.98-0.950.520.62
1.0-0.94-0.970.97-0.981.00.99-0.94-0.94-0.98-0.951.0-0.961.0-0.4-0.48
-0.931.00.92-0.970.98-0.94-0.950.99-0.940.981.0-0.940.97-0.940.520.61
-0.980.980.97-0.971.0-0.98-0.980.99-0.980.980.99-0.980.98-0.980.420.57
-0.941.00.94-0.970.99-0.95-0.960.99-0.951.00.99-0.950.97-0.950.50.6
1.0-0.94-0.980.98-0.981.01.0-0.941.0-0.94-0.98-0.95-0.941.0-0.4-0.49
-0.950.970.91-0.950.98-0.95-0.950.98-0.960.970.980.97-0.94-0.940.460.55
1.0-0.94-0.970.98-0.981.01.0-0.951.0-0.94-0.98-0.951.0-0.94-0.4-0.49
-0.390.520.26-0.550.42-0.41-0.450.52-0.40.520.420.5-0.40.46-0.40.74
-0.490.610.47-0.570.57-0.49-0.520.62-0.480.610.570.6-0.490.55-0.490.74
Click cells to compare fundamentals

Achilles Therapeutics Account Relationship Matchups

Achilles Therapeutics income statement Accounts

202020212022202320242025 (projected)
Interest Expense215K531K3.1M7.3M8.4M8.8M
Ebit(33.7M)(61.1M)(82.1M)(75.2M)(67.7M)(71.0M)
Net Income Applicable To Common Shares(14.0M)(33.2M)(61.1M)(71.2M)(64.1M)(60.9M)
Tax Provision3K37K111K27K31.1K39.2K
Depreciation And Amortization778.0K3.3M3.7M4.7M5.4M2.8M
Selling General Administrative11.1M22.0M21.1M17.0M19.6M16.7M
Gross Profit(778.0K)(3.3M)(3.7M)(4.7M)(4.3M)(4.0M)
Other Operating Expenses33.7M64.2M78.4M75.3M86.5M58.4M
Operating Income(33.7M)(64.2M)(78.4M)(75.3M)(67.7M)(71.1M)
Net Income From Continuing Ops(33.2M)(61.1M)(71.2M)(75.1M)(67.6M)(71.0M)
Research Development22.6M42.2M57.3M67.6M77.8M43.7M
Ebitda(33.0M)(57.8M)(78.4M)(70.4M)(63.4M)(66.6M)
Cost Of Revenue778.0K3.3M3.7M4.7M5.4M2.8M
Total Operating Expenses33.7M64.2M78.4M75.3M86.5M58.4M
Reconciled Depreciation772K3.3M3.7M4.4M5.1M2.7M
Income Before Tax(33.2M)(61.1M)(71.1M)(69.2M)(62.3M)(65.4M)
Total Other Income Expense Net531K3.1M7.3M6.1M7.0M3.7M
Net Income(33.2M)(61.1M)(71.2M)(69.7M)(62.7M)(65.8M)
Income Tax Expense3K37K111K491K564.7K592.9K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.66)
Return On Assets
(0.27)
Return On Equity
(0.44)
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.